US 11807853
Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
granted A61KA61K31/136A61K31/137
Quick answer
US patent 11807853 (Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer) held by The Board of Regents of the University of Texas System expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/136, A61K31/137, A61K31/337, A61K31/52